# Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)

> **NCT02894385** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 29 (actual)

## Conditions studied

- Pharmacokinetics
- Hepatic Insufficiency
- Renal Insufficiency

## Interventions

- **DRUG:** BAY1841788

## Key facts

- **NCT ID:** NCT02894385
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-13
- **Primary completion:** 2017-04-10
- **Final completion:** 2017-12-15
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2019-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02894385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02894385, "Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02894385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*